Di Nunno Vincenzo, Franceschi Enrico, Tosoni Alicia, Gatto Lidia, Bartolini Stefania, Brandes Alba Ariela
Department of Oncology, Azienda Unità Sanitaria Locale (AUSL) Bologna, Bologna, Italy.
Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Front Oncol. 2022 Jul 7;12:891543. doi: 10.3389/fonc.2022.891543. eCollection 2022.
The glioma-associated tumor microenvironment involves a multitude of different cells ranging from immune cells to endothelial, glial, and neuronal cells surrounding the primary tumor. The interactions between these cells and glioblastoma (GBM) have been deeply investigated while very little data are available on patients with lower-grade gliomas. In these tumors, it has been demonstrated that the composition of the microenvironment differs according to the isocitrate dehydrogenase status (mutated/wild type), the presence/absence of codeletion, and the expression of specific alterations including H3K27 and/or other gene mutations. In addition, mechanisms by which the tumor microenvironment sustains the growth and proliferation of glioma cells are still partially unknown. Nonetheless, a better knowledge of the tumor-associated microenvironment can be a key issue in the optic of novel therapeutic drug development.
胶质瘤相关的肿瘤微环境涉及多种不同类型的细胞，从免疫细胞到原发性肿瘤周围的内皮细胞、神经胶质细胞和神经元细胞。这些细胞与胶质母细胞瘤（GBM）之间的相互作用已得到深入研究，而关于低级别胶质瘤患者的数据却非常少。在这些肿瘤中，已经证明微环境的组成根据异柠檬酸脱氢酶状态（突变型/野生型）、是否存在共缺失以及包括H3K27和/或其他基因突变在内的特定改变的表达而有所不同。此外，肿瘤微环境维持胶质瘤细胞生长和增殖的机制仍然部分未知。尽管如此，更好地了解肿瘤相关微环境可能是新型治疗药物开发前景中的一个关键问题。
